Brought to you by:
SCVS 2023: DAPT linked to better post-TCAR outcomes versus other drug regimens
Recent data presentations have revealed reduced risks of stroke and mortality among transcarotid artery revascularization (TCAR) patients who receive dual antiplatelet therapy (DAPT)—both preoperatively and at discharge—as compared to other drug regimens. Researchers believe these findings underscore the importance of…
SCVS 2023: DAPT shows higher survival rate in patients with low WIfI scores, study indicates
A retrospective cohort study presented at the 2023 Society for Clinical Vascular Surgery (SCVS) Annual Symposium in Miami (March 25–29) has found lower-extremity bypass patients who received dual antiplatelet therapy or anticoagulation (DAPT/AC) postoperatively had a higher 30-day survival rate.…
DAPT linked to better post-TCAR outcomes versus other drug regimens
Dual antiplatelet therapy (DAPT) has demonstrated improved clinical outcomes, including reduced in-hospital stroke and mortality risks, compared to other medication regimens in carotid disease patients who undergo stent placement via a transcarotid artery revascularization (TCAR) procedure. This is the key…